Aileron Therapeutics, a biopharmaceutical company, has appointed Steven Kafka, PhD as its first chief financial officer (CFO) and vice president, finance and operations.
Kafka will lead Aileron’s strategic and operational finance activities, direct corporate communications, human resources, and operations and support the company`s business development effort. He will report to Joseph Yanchik III, chief executive officer (CEO).
Kafka brings more than 12 years of experience in finance, strategic planning, business development, operations, corporate communications and early commercial development. Before joining Aileron, he served as vice president, finance for Infinity Pharmaceuticals, where he led finance, investor and public relations and business operations, and was a key member of the team that recently secured an alliance with Purdue Pharma and Mundipharma worth up to US$500m over five years.
Previously, Kafka was senior director, finance, at Millennium Pharmaceuticals, where as an inaugural member of the Velcade product team he drove strategic planning and alliance management efforts with partner Johnson & Johnson. Earlier, he was a senior engagement manager with Strategic Decisions Group, providing product and portfolio strategy consulting to large pharmaceutical companies.
Kafka earned his PhD from Harvard University and his BA with distinction and honours from Stanford University.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.